Each year the IASLC supports young researchers in order to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine worldwide. Applications for Fellowship and Young Investigator awards are taken each January. Three candidates representing North America, Asia and Europe are awarded research funding for one year after competing with a global pool of applicants. Applications are evaluated by an international scientific review panel for their merit, innovation and potential impact on the management of lung cancer.
The Prevent Cancer Foundation (PCF) will jointly sponsor awards focused on lung cancer prevention and translational research, supported through educational grants from Eli Lilly. Additional unrestricted awards in any field of lung cancer research are supported by educational grants from Amgen, Genentech, Celgene, Merck KGaA, Eli Lilly, the IASLC and other sponsors.
Boehringer Ingelheim in collaboration with the IASLC have created the Chinese Lung Cancer Fellowship Award to enable a fellow to come to the United States for a one-year research project. The goal of this fellowship is to reward scientific excellence and to encourage innovative and collaborative investigation in the fields of lung cancer prevention, diagnosis, and translational research with a potential impact on the management of lung cancer. The pool of applications are reviewed and scored by an international committee of experts who send there recommendations to the board of directors for final selection.
Lung Cancer Foundation of America (LCFA) in partnership with the IASLC has created a prestigious Lung Cancer Research Grant that is awarded every two years. The award is given to someone who seeks to make an immediate and relevant impact on cancer patient care or to interpret the results of a clinical trial from a molecular basis to help inform decisions in future clinical trials.